

Impact of smoking cessation on skeletal muscle

Submission date 14/07/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 14/07/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 21/01/2020	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Nick Hopkinson

Contact details

Royal Brompton Hospital
Fulham Road
London
United Kingdom
SW3 6NP

-

n.hopkinson@imperial.ac.uk

Additional identifiers

Protocol serial number

8238

Study information

Scientific Title

Impact of smoking cessation on skeletal muscle atrophy and hypertrophy pathways in chronic obstructive pulmonary disease (COPD)

Study objectives

Our hypothesis is that smoking cessation in patients with chronic obstructive pulmonary disease (COPD) will lead to an increase in skeletal muscle bulk and endurance and that this will be associated with alterations in the pathways controlling skeletal muscle atrophy and hypertrophy including the Akt/FOXO/atrogene, mTOR and MyoD and myostatin pathways. We also propose that smoking cessation will lead to a more oxidative fibre type with an increase in the expression of type I myosin and reduction in the expression of type II myosin heavy chains. We will investigate this by making detailed assessment of skeletal muscle function and examining biopsies from the quadriceps muscle before and after smoking cessation.

In parallel with this we will study the effect of smoking cessation on lung function, exercise capacity and systemic inflammation.

Ethics approval required

Old ethics approval format

Ethics approval(s)

UCLH Committee Alpha approved, ref: 09/H0715/37

Study design

Single-centre observational non-randomised diagnosis and screening cohort study

Primary study design

Observational

Study type(s)

Diagnostic

Health condition(s) or problem(s) studied

Effect of smoking cessation on skeletal muscle strength in people with chronic obstructive pulmonary disease (COPD) and in smokers with normal lung function

Interventions

Smoking cessation advice, counselling and pharmacotherapy as clinically indicated. This may include NRT and varenicline. Outcomes will be assessed 8 weeks after the quit date.

Intervention Type

Mixed

Primary outcome(s)

Current primary outcome measure as of 18/10/2019:

Dynamic hyperinflation during cycle ergometry measured at 8 weeks after quit date

Previous primary outcome measure:

Activity of the IGF-1 PI3K/Akt/FOXO/atrogene pathway and the mTOR pathway in muscle biopsy specimens, measured at 8 weeks after quit date

Key secondary outcome(s)

Current secondary outcome measures as of 18/10/2019:

Measured at 8 weeks after quit date:

1. Quadriceps endurance
2. Quadriceps strength

Previous secondary outcome measures:

Measured at 8 weeks after quit date:

1. Dynamic hyperinflation during cycle ergometry
2. MyoD and myostatin protein and mRNA levels
3. Quadriceps endurance
4. Quadriceps strength

Completion date

01/10/2020

Eligibility

Key inclusion criteria

1. Consenting adult smokers who wish to quit
2. Both COPD patients who smoke and smokers with normal lung function
3. Male and female, lower age limit of 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

The presence of significant co-morbidity judged likely to have a significant impact on muscle strength

Date of first enrolment

01/11/2009

Date of final enrolment

01/10/2020

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Royal Brompton Hospital
London
United Kingdom
SW3 6NP

Sponsor information

Organisation
Imperial College London (UK)

ROR
<https://ror.org/041kmwe10>

Funder(s)

Funder type
Research council

Funder Name
Medical Research Council (MRC) (UK)

Alternative Name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC

Funding Body Type
Government organisation

Funding Body Subtype
National government

Location
United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan
All data generated or analysed during this study will be included in the subsequent results publication

IPD sharing plan summary

Other

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes